Search Results
"Stathmin-2: An Emerging Therapeutic Target in TDP-43 Proteinopathies"
2022 Annual ALS ONE Research Symposium: Dr. Kevin Eggan/Stathmin2 Update on biology and therapy.
Expanding Mechanisms and Therapeutic Targets for ALS
TDP-43 in nerve bundles- a novel diagnostic biomarker for Amyotrophic Lateral Sclerosis
Elizabeth Head, MA, PhD - TDP-43 pathology in Down Syndrome and Alzheimer Disease
F. E. Baralle - New insights in TDP-43 aggregation processes
Maiko Uemura, MD, PhD - Distinct characteristics of limbic-predominant age-related TDP-43...
K. Talbot - Physiological models of TDP-43 related amyotrophic lateral sclerosis
2022 Annual ALS ONE Research Symposium: Dr. Aaron Gitler/New ALS splicing targets.
Updates on C9orf72 and TDP-43 Research from Dr Jeffrey Rothstein
KGRI Lecture Series: Seminar on ALS Part 3 (Don W. Cleveland)
"ALS, Mouse Models, and Therapeutic Strategies"
